GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bristol-Myers Squibb Co (BUE:BMY) » Definitions » Cyclically Adjusted PS Ratio

Bristol-Myers Squibb Co (BUE:BMY) Cyclically Adjusted PS Ratio : 2.68 (As of May. 23, 2024)


View and export this data going back to . Start your Free Trial

What is Bristol-Myers Squibb Co Cyclically Adjusted PS Ratio?

As of today (2024-05-23), Bristol-Myers Squibb Co's current share price is ARS17718.50. Bristol-Myers Squibb Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ARS6,620.24. Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio for today is 2.68.

The historical rank and industry rank for Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio or its related term are showing as below:

BUE:BMY' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.27   Med: 4.69   Max: 7
Current: 2.27

During the past years, Bristol-Myers Squibb Co's highest Cyclically Adjusted PS Ratio was 7.00. The lowest was 2.27. And the median was 4.69.

BUE:BMY's Cyclically Adjusted PS Ratio is ranked worse than
52.96% of 742 companies
in the Drug Manufacturers industry
Industry Median: 2.13 vs BUE:BMY: 2.27

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Bristol-Myers Squibb Co's adjusted revenue per share data for the three months ended in Mar. 2024 was ARS4,941.306. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ARS6,620.24 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Bristol-Myers Squibb Co Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bristol-Myers Squibb Co Cyclically Adjusted PS Ratio Chart

Bristol-Myers Squibb Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.10 4.67 4.21 4.34 2.85

Bristol-Myers Squibb Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.05 3.65 3.25 2.85 2.91

Competitive Comparison of Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio falls into.



Bristol-Myers Squibb Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=17718.50/6620.24
=2.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bristol-Myers Squibb Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Bristol-Myers Squibb Co's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=4941.306/131.7762*131.7762
=4,941.306

Current CPI (Mar. 2024) = 131.7762.

Bristol-Myers Squibb Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 18.932 100.560 24.809
201409 19.767 100.428 25.937
201412 21.724 99.070 28.896
201503 21.265 99.621 28.129
201506 22.692 100.684 29.700
201509 22.800 100.392 29.928
201512 32.930 99.792 43.484
201603 38.170 100.470 50.063
201606 40.557 101.688 52.557
201609 43.729 101.861 56.572
201612 49.385 101.863 63.888
201703 45.476 102.862 58.259
201706 51.403 103.349 65.542
201709 55.969 104.136 70.825
201712 63.328 104.011 80.233
201803 63.801 105.290 79.851
201806 86.955 106.317 107.778
201809 128.009 106.507 158.380
201812 137.576 105.998 171.034
201903 141.364 107.251 173.691
201906 171.210 108.070 208.768
201909 205.598 108.329 250.098
201912 244.794 108.420 297.528
202003 296.355 108.902 358.604
202006 306.421 108.767 371.242
202009 341.699 109.815 410.034
202012 399.962 109.897 479.591
202103 440.378 111.754 519.276
202106 492.285 114.631 565.913
202109 506.730 115.734 576.968
202112 544.964 117.630 610.504
202203 577.943 121.301 627.852
202206 665.595 125.017 701.582
202209 725.671 125.227 763.626
202212 901.138 125.222 948.306
202303 1,059.926 127.348 1,096.784
202306 1,281.751 128.729 1,312.095
202309 1,859.279 129.860 1,886.722
202312 2,037.972 129.419 2,075.085
202403 4,941.306 131.776 4,941.306

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Bristol-Myers Squibb Co  (BUE:BMY) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Bristol-Myers Squibb Co Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Bristol-Myers Squibb Co (BUE:BMY) Business Description

Address
430 East 29th Street, 14th Floor, New York, NY, USA, 10016
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.